Prostate:未经激素治疗前列腺癌中tSTAT3、pSTAT3 727和pSTAT3 705的表达研究

2019-04-07 AlexYang MedSci原创

信号转导和激活转录因子3(STAT3)途径在一些恶性肿瘤中持续性的激活,其中包括了前列腺癌(PCa)。最近,有研究人员在2个未经激素治疗的局部PCa患者群体的组织芯片中,调查了总STAT3(tSTAT3)和2种激活形式的磷酸化STAT3(pSTAT3 727和pSTAT3 705)的表达情况,并且分析了表达与疾病结果的相关性情况。研究发现,tSTAT3、pSTAT3 727和pSTAT3 705在

信号转导和激活转录因子3(STAT3)途径在一些恶性肿瘤中持续性的激活,其中包括了前列腺癌(PCa)。最近,有研究人员在2个未经激素治疗的局部PCa患者群体的组织芯片中,调查了总STAT3(tSTAT3)和2种激活形式的磷酸化STAT3(pSTAT3727和pSTAT3705)的表达情况,并且分析了表达与疾病结果的相关性情况。

研究发现,tSTAT3、pSTAT3727和pSTAT3705在良性腺体上皮细胞的细胞核中表达水平要比癌症腺体中更高。细胞质中的tSTAT3水平比良性腺体中更高。癌症腺体中低pSTAT3727和pSTAT3705水平患者与那些更高水平的患者相比,生化复发时间减少。在MalmÖ群体中,研究人员并未观察到细胞核或者细胞质中tSTAT3与生化复发相关的趋势;而在Dublin群体中,研究人员发现更高的细胞质tSTAT3水平与生化复发时间的减少相关。另外,将tSTAT3和pSTAT3表达数据附加到格林森得分或者病理性T阶段中并没有改善预后值。

最后,研究人员指出,未经激素治疗PCa患者的癌症前列腺腺体上皮细胞中低pSTAT3727和pSTAT3705表达与疾病更快的恶化相关。然而,pSTAT3和tSTAT3的表达并未改善格林森得分或者病理性T阶段的预后值,也许并不是一个良好的生物标记。

原始出处:

Krzyzanowska A, Don-Doncow N, Marginean FE et al. Expression of tSTAT3, pSTAT3 727 , and pSTAT3 705 in the epithelial cells of hormone-naïve prostate cancer. Prostate. 24 Mar 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-04-11 ylzr123

    好文章,点赞啦!认真学习,谢谢分享给广大同好!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-04-09 清风拂面

    谢谢分享学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-04-09 李研东
  5. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-04-09 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-04-09 zhouqu_8
  7. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=364483, encodeId=31c0364483b9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Apr 11 15:45:17 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364357, encodeId=2a6636435e36, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Apr 09 12:32:41 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307416, encodeId=b89c130e416e4, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348971, encodeId=893013489e13a, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364476, encodeId=76f513644e6b3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602143, encodeId=9f4116021436c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605344, encodeId=10aa1605344d7, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Tue Apr 09 04:19:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040431, encodeId=072d104043115, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 16:19:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-04-07 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Oncogenesis:CUL4B能够通过与SOX4形成正反馈循环促进前列腺癌恶化

怎样从恶性疾病中区分无痛性疾病在前列腺癌(PCa)的治疗中仍旧是一个巨大的挑战。Cullin 4B (CUL4B)是一种支架蛋白并且在多种人类恶性肿瘤中表现出了致瘤活性。最近,有研究人员利用PCa组织样本、细胞系和异种种植模型确定了是否CUL4B能够导致PCa恶化和转移。研究发现,CUL4B的表达与PCa的恶化过程相关。CUL4B的表达能够促进PCa细胞的增殖、上皮间质转化和PCa细胞的转移,而C

NCCN临床实践指南:前列腺癌(2019.V1)

2019年3月,美国国家综合癌症网络(NCCN)发布了前列腺癌指南2019年第1版,指南主要内容涉及: 指南更新摘要 初始前列腺癌诊断 非常低风险:初始治疗、辅助治疗 低风险:初始治疗、辅助治疗 中间风险:初始治疗、辅助治疗 高风险,极高风险:初始治疗、辅助治疗 检测,复发 前列腺切除术失败 放射治疗复发 系统治疗 M1 CRPC随后系统治疗 生存寿命评估原则 影像检查原则 积极监测和观察原则 放

盘点:前列腺癌与治疗进展盘点

【1】Oncogene:Karyopherin β1的抑制能够抑制前列腺癌的生长 前列腺癌(PCa)的起始和进展需要大量的致瘤信号途径的激活。在细胞转化期间,致瘤因子在核质转运的过程受Karyopherin蛋白的调节。然而,核转运蛋白在PCa进展中的作用还没有很好的解释。最近,有研究人员报道了一个关键的Karyopherin β亚基-KPNB1,在晚期前列腺癌中高度表达。进一步的研究

盘点:前列腺癌与相关机制

【1】Nucleic Acids Res:揭示长链非编码RNA PCAT1促进去势抵抗性前列腺癌进展的新机制 http://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkz108/5324447在PTEN缺失的前列腺癌中,AKT信号通路的激活依赖于雄激素受体信号通路的抑制。HLPP/FKBP51/IKKα蛋白复合体在AKT和NF-

EBioMedicine:前列腺癌治疗药物新发现

基因组规模的代谢模型(GEMs)为癌症代谢提供了新的认识,并且已经用于鉴定潜在的生物标记和药物靶标。药物重定位是一种既省时又省力的药物发现的方法,并且可以与GEMs一起用于癌症的有效治疗。最近,有研究人员构建了一个前列腺癌(PRAD)特异性GEM,用来探索前列腺癌代谢,并且探索新的可以用于有效癌症治疗的药物。研究人员通过使用前列腺癌GEM模型对多于1000中不同的药物进行了整体的基因表达分析,并预

Prostate Cancer P D: 前列腺癌SLCO基因表达与格林森等级和雄激素阻断治疗后变化相关性分析

雄激素阻断治疗(ADT)后,SLCO编码的转运蛋白与去势难治性前列腺癌(CRPC)的恶化相关。尽管比CRPC组织中的表达水平更低,SLCO编码的转运蛋白可能在原发性前列腺癌(PCa)对ADT和生化复发响应中具有作用。最近,有研究人员系统性的探索了11个人类SLCO基因的表达在正常的前列腺(NP)和ADT治疗和未治疗的原发性PCa组织中的表达情况,包括了阿比特龙新辅助治疗的肿瘤。研究发现,在PCa中